{"groups":[{"description":"ARM A: Patients receive one of the four chemotherapy regimens\n\nARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Chemotherapy Arm (Arm A)"},{"description":"ARM B: Patients receive bevacizumab in addition to the chemotherapy regimen as in arm A\n\nARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.\n\nARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm IIA.\n\nARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.\n\nARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.","id":"FG001","title":"Chemotherapy+Bevacizumab (Arm B)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"85"},{"groupId":"FG001","numSubjects":"68"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"58"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"22"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"25"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"Alternative therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Other complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"9"}],"type":"Not start protocol therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"10"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician discretion"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Patient non-compliance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"203"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"188"},{"groupId":"FG001","numSubjects":"183"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"194"}],"type":"Start Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"159"},{"groupId":"FG001","numSubjects":"200"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"E1305 was activated on August 8, 2008 and closed on February 11,2015, with final accrual of 403 patients."}